| 摘要 |
The invention relates to novel radiotherapeutic formulations containing <224>Ra and methods for their production. The invention discloses, in particular, radiotherapeutic formulations comprising at least one salt of the isotope <224>Ra, which are characterized in that the content of other radionuclides, in particular, the respective content of certain longeval radionuclides does not exceed a specific numerical value in mBq/g. The invention also relates to a method for producing radiotherapeutic formulations of this type, which is characterized by the following steps: after at least one centrifugation of an aqueous suspension of the compound <228>Th(OH)4 and optionally after the resuspension of the raw sediment obtained in said centrifugation, the precipitated <228>Th(OH)4 sediment is separated. The supernatant solution of a <224>Ra salt that has been obtained is subsequently subjected to sterile filtration and is then made up to the required dose. Finally, said solution is sterilized and bottled in ampoules in a manner known per se.
|
